Straits Times Index
3,230.55 +21.37 (+0.67%) Nikkei
26,781.68 +176.84 (+0.66%) Hang Seng
20,697.36 +581.16 (+2.89%) FTSE 100
7,585.46 +20.54 (+0.27%) BTC-USD
28,890.59 +333.44 (+1.17%) CMC Crypto 200
625.79 -3.71 (-0.59%)
Repare Therapeutics Inc. (RPTX)
After hours:
- Business Wire
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
- Zacks
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
